Mesa Laboratories Inc: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Jul 30, 2019 and accepted by EDGAR at Jul 30, 2019, 08:17 ET.
Management's discussion and analysis
As filed, 23,272 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Forward Looking Statements
This report contains information that may constitute "forward-looking statements.” Generally, the words "believe," "expect," “will,” “estimate,” "anticipate," "intend," "project," and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events, or developments that we expect or anticipate will occur in the future — including statements relating to revenues growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to those described in Part II, "Item 1A. Risk Factors" and elsewhere in this report and in our Annual Report on Form 10-K for the year ended March 31, 2019, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.
General Discussion
We pursue a strategy of focusing primarily on quality control products and services, which are sold into niche markets that are driven by regulatory requirements. We prefer markets in which we can establish a strong presence and achieve high gross margins. We are organized into four divisions, or segments, across ten physical locations. Our Sterilization and Disinfection Control Division manufactures and sells biological, cleaning, and chemical indicators. Biological, cleaning, and chemical indicators are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. The division also provides testing and laboratory services, mainly to the dental industry. Our Instruments Division designs, manufactures, and markets quality control instruments and disposable products utilized in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. Our Cold Chain Monitoring Division designs, develops, and markets systems which are used to monitor various environmental parameters such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. Our Cold Chain Packaging Division ("the Packaging Division"), which we plan to exit no later than March 31, 2020, provides thermal packaging products such as coolers, boxes, insulation materials, and phase-change products to control temperature during the customer’s transport of their own products.
Our revenues come from product sales, which include hardware, software, and consumables; as well as services, which include installation, discrete maintenance services, and ongoing maintenance contracts. Product sales (hardware, software, and consumables) are dependent on several factors, including general economic conditions, both domestic and international, customer capital spending trends, competition, introduction of new products, and acquisitions. Sterilization and disinfection control products and most products in our Packaging Division are disposable and are used on a routine basis, thus product sales are less sensitive to general economic conditions. Instrument products and cold chain monitoring products and systems have a longer life, and their purchase by our customers is somewhat discretionary, so sales are more sensitive to general economic conditions. Cold chain monitoring and instruments products may be sold in conjunction with a perpetual or subscription-based software license, which may be required for the related hardware to function. Service demand is driven by our customers’ quality control and regulatory environments, which require periodic repair and recalibration or certification of our instrument products and cold chain monitoring systems. We typically evaluate costs and pricing annually. Our policy is to price our products competitively and, where possible, we pass along cost increases in order to maintain our margins.
Gross profit is affected by our product mix, manufacturing efficiencies, and price competition. Historically, as we have integrated our acquisitions and taken advantage of manufacturing efficiencies, our gross margin percentages for some products have improved. There are, however, differences in gross margin percentages between product lines, and ultimately the mix of sales will continue to impact our overall gross margin.
During the three months ended June 30, 2019, we completed a business combination (the “IBP Acquisition”) whereby we acquired the common stock of IBP Medical GmbH ("IBP"), a company whose business manufactures medical meters used to test various parameters of dialysis fluid (dialysate), and the proper calibration and operation of a dialysis machine.
General Trends
Our strategic financial objectives include growth both organically and through further acquisitions. During the three months ended June 30, 2019, we worked to maximize the efficiency of our operations to prepare for future growth, including relocating and consolidating most of the administrative functions of our Packaging Division from Markham, Canada to our corporate headquarters in Lakewood, Colorado; hiring key personnel to our operations and sales and marketing teams, and leveraging The Mesa Way, our customer-centric, lean-based system for continuously improving and operating a set of high-margin, niche businesses.
The markets for sterilization and disinfection control products remain strong, as the disposable nature of these products makes them less sensitive to general economic conditions. The worldwide market for sterilization and disinfection control products is growing as more countries focus on verifying the effectiveness of sterilization and disinfection processes.
Demand for our instruments products and cold chain services and monitoring systems remains solid and we strive to continue to grow revenues going forward. In general, our instruments products and cold chain monitoring systems are more impacted by general economic conditions than our sterilization and disinfection control and cold chain packaging products. As a result, uncertainty about global economic conditions may cause businesses to postpone spending in response to tighter credit, unemployment, negative financial news and/or declines in income or asset values. Worldwide and regional economic conditions could also reduce the demand for our products and services, as our customers reduce or delay capital equipment and other types of purchases.
We are working on several research and development projects that, if completed, may result in enhanced or new products for both existing customers and new markets. We are hopeful that we will have enhanced or new products and services available for sale in the coming year.
Overall revenues increased 5% for the three months ended June 30, 2019. Organic revenues growth by reporting segment was as follows:
| Three Months Ended June 30, 2019 | |
|---|---|
| Sterilization and Disinfection Control | 7% |
| Instruments | 4% |
| Cold Chain Monitoring | (13%) |
| Cold Chain Packaging | (28%) |
| Total Company | 1% |
| Total Company excluding Cold Chain Packaging | 3% |
As previously announced, during the year ended March 31, 2019, we made the decision to exit the packaging business by or before March 31, 2020. We have stopped providing consulting services, and we are no longer seeking or accepting new customers. We have reduced the division's costs by relocating most of the administrative functions to our headquarters in Lakewood, Colorado, and eliminating the division's sales force. Throughout the year ending March 31, 2020, we intend to assist our customers in transitioning their business to other packaging vendors.
Results of Operations
(Dollars in thousands)
The following table sets forth, for the periods indicated, Condensed Consolidated Statements of Income data. The table and the discussion below should be read in conjunction with the accompanying Condensed Consolidated Financial Statements and the notes thereto appearing elsewhere in this report:
| Three Months Ended June 30, 2019 | 2018 | Change | Percent Change | |
|---|---|---|---|---|
| Revenues | $26,288 | $25,142 | $1,146 | 5% |
| Cost of revenues | 10,149 | 10,051 | 98 | 1% |
| Gross profit | $16,139 | $15,091 | $1,048 | 7% |
| Gross profit margin | 61% | 60% | 1% | |
| Operating expenses | ||||
| Selling | $2,208 | $1,890 | $318 | 17% |
| General and administrative | 7,520 | 7,600 | (80) | (1%) |
| Research and development | 1,019 | 837 | 182 | 22% |
| Total operating expenses | $10,747 | $10,327 | $420 | 4% |
| Operating income | $5,392 | $4,764 | $628 | 13% |
| Net income | 4,597 | 4,230 | 367 | 9% |
| Net income margin | 17% | 17% | 0% |
Page 18
Revenues
The following tables summarize our revenues by source:
| Three Months Ended June 30, 2019 | 2018 | Change | Percent Change | |
|---|---|---|---|---|
| Sterilization and Disinfection Control | $12,110 | $11,348 | $762 | 7% |
| Instruments | 9,544 | 8,731 | 813 | 9% |
| Cold Chain Monitoring | 3,317 | 3,223 | 94 | 3% |
| Cold Chain Packaging | 1,317 | 1,840 | (523) | (28%) |
| Total | $26,288 | $25,142 | $1,146 | 5% |
Three months ended June 30, 2019 versus June 30, 2018
Sterilization and Disinfection Control revenues for the three months ended June 30, 2019 increased 7% as a result of organic revenues growth, which was achieved primarily through volume increases with existing customers and modest price increases. Additionally, the comparable period ending June 30, 2018 was negatively affected by our inability to fulfill some of the division's orders on a timely basis as we completed the move of our Sterilization and Disinfection Control business into our new Bozeman, Montana facility.
Instruments revenues for the three months ended June 30, 2019 increased 9%, due to organic revenues growth of 4% and the acquisition of IBP during the three months ended June 30, 2019.
Cold Chain Monitoring revenues increased 3% for the three months ended June 30, 2019 as a result of the acquisition of Point Six Wireless, LLC ("Point Six") in the prior year, partially offset by an organic revenues decline of 13%. The organic revenues decline was primarily due to a decrease of $501 of contracted revenues as compared to the prior year, as revenues from contract renewals were delayed due to the timing of implementation of certain product updates. Revenues in this division have historically fluctuated quarter over quarter due to the timing of performance obligations and the nature and timing of orders and installations within any given quarter.
Cold Chain Packaging revenues decreased 28% for the three months ended June 30, 2019 as a result of our decision to exit the business and cease accepting new customers, completing our sales contract with our largest customer, and our assisting of our current customers in transitioning their business to other vendors.
Gross Profit
The following summarizes our gross profit by segment:
| Three Months Ended June 30, 2019 | 2018 | Change | Percent Change | |
|---|---|---|---|---|
| Sterilization and Disinfection Control | $8,505 | $7,812 | $693 | 9% |
| Gross profit margin | 70% | 69% | 1% | |
| Instruments | 6,063 | 5,633 | 430 | 8% |
| Gross profit margin | 64% | 65% | (1%) | |
| Cold Chain Monitoring | 1,244 | 1,464 | (220) | (15%) |
| Gross profit margin | 38% | 45% | (7%) | |
| Cold Chain Packaging | 327 | 182 | 145 | 80% |
| Gross profit margin | 25% | 10% | 15% | |
| Total gross profit | $16,139 | $15,091 | $1,048 | 7% |
| Gross profit margin | 61% | 60% | 1% |
Three Months Ended June 30, 2019 versus June 30, 2018
Sterilization and Disinfection Control gross profit margin percentage increased slightly during the three months ended June 30, 2019 primarily as a result of efficiencies gained from higher sales volumes and to a lesser extent, as a result of modest price increases.
Instruments gross margin percentage decreased 1 percentage point during the three months ended June 30, 2019, primarily due to product and service mix.
Cold Chain Monitoring gross profit percentage decreased 7 percentage points during the three months ended June 30, 2019 primarily due to lower than planned volumes along with the impact of the integration of the Point Six acquisition. As previously discussed, contracted revenues declined $501 compared to the prior year, as contract renewals were delayed due to the timing of implementation of certain product updates. Many of the costs associated with our contracted revenues, such as salaries expenses, are partially fixed, and as such, the lower contracted revenues resulted in lower margins during the three months ended June 30, 2019. Additionally, we have not completed the integration of the Point Six acquisition, which has resulted in increased costs on a per unit basis, but we expect it will be completed no later than March 31, 2020. After the integration is complete, we expect gross margin percentage for this division to be 40%- 45%.
Cold Chain Packaging gross profit margin increased 15 percentage points during the three months ended June 30, 2019 primarily as a result of implementing price increases during the three months ended March 31, 2019 as part of our plan to exit the business by March 31, 2020. Also contributing to the increase were lower operating and personnel expenses and the completion of our sales contract with the division's largest customer which historically was one of our lower margin customers as a percentage of revenues.
Operating Expenses
Operating expenses increased 4% for the three months ended June 30, 2019 as compared to the prior year as follows:
Selling
Three Months Ended June 30, 2019 versus June 30, 2018
Selling expense is driven primarily by labor costs, including salaries and commissions; accordingly, it may vary with sales levels. Selling expense increased 17% during the three months ended June 30, 2019, as we back-filled open sales and marketing positions and incurred higher professional services costs associated with investments in our technological infrastructure in an effort to modernize our marketing program. As a percentage of revenues, selling expense was 8% for both the three months ended June 30, 2019 and June 30, 2018. We plan to continue strategically investing in sales and marketing resources in order to further increase organic revenues growth.
General and Administrative
Three Months Ended June 30, 2019 versus June 30, 2018
Labor costs, including non-cash stock-based compensation and amortization of intangible assets drive the substantial majority of general and administrative expense. General and administrative expenses decreased 1% during the three months ended June 30, 2019, due primarily to decreased amortization of intangible assets as we wind down our Packaging Division, partially offset by increased equity-based compensation expense.
Research and Development
Three Months Ended June 30, 2019 versus June 30, 2018
Research and development expense is predominantly comprised of labor costs and costs of third-party consultants. Research and development expenses for the three months ended June 30, 2019 increased 22%, due to increases in salary expense as we staff our engineering department to support the demands of our organic revenues growth strategy by making incremental investments in research and development to enhance existing products.
Other Expense
Other expense for the three months ended June 30, 2019 is composed primarily of interest expense associated with our Credit Facility, gains and losses on sales of property, plant and equipment, and gains and losses on foreign currency transactions.
Net Income
Our income tax rate varies based upon many factors but in general, we anticipate that on a go-forward basis, our effective tax rate will be approximately 26%, plus or minus the impact of excess tax benefits and deficiencies associated with share-based payment awards to employees; see Note 8. “Income Taxes” within Item 1. Financial Statements for additional discussion. The excess tax benefits and deficiencies associated with share-based payment awards to our employees have caused and, in the future, may cause large fluctuations in our realized effective tax rate based on timing, volume, and nature of stock options exercised under our share-based payment program. Net income for the three months ended June 30, 2019 varied with the changes in revenues, gross profit, and operating expenses (which includes $1,672 and $868 of non-cash amortization of intangible assets and stock-based compensation, respectively).
Liquidity and Capital Resources
Our sources of liquidity include cash generated from operations, working capital, capacity under our Credit Facility, and potential equity and debt offerings. We believe that cash generated from these sources will be sufficient to meet our short-term and long-term needs. Our more significant uses of resources have historically included long-term capital equipment expenditures, payment of debt obligations, quarterly dividends to shareholders, and acquisitions. Working capital is the amount by which current assets exceed current liabilities. We had working capital of $12,501 and $9,962 at June 30, 2019, and March 31, 2019, respectively.
Given our cash flow projections and unused capacity on our line of credit that is available until March 1, 2022, our liquidity is strong and is expected to meet our ongoing cash and debt service requirements for our general business needs. Interest-bearing debt of $20,000 and $23,000 was outstanding at June 30, 2019, and March 31, 2019, respectively. The Term Loan requires 20 quarterly principal payments, which began on March 31, 2017, in the amount of $250,000 (increasing by $125,000 each year up to $750,000 in the fifth year). The remaining balance of principal and accrued interest are due on March 1, 2022. We were in compliance with all loan agreements at June 30, 2019 and for all prior years presented and have met all debt payment obligations.
We have recorded an estimated litigation accrual of $3,300 on our Condensed Consolidated Balance Sheets, which we expect to pay during the three months ending September 30, 2019; see Note 9. “Commitments and Contingencies” within Item 1. Financial Statements.
We routinely evaluate opportunities for strategic acquisitions. Future material acquisitions may require that we obtain additional capital, assume third party debt or incur other long-term obligations. We believe that we have the option to utilize both equity and debt instruments as vehicles for the long-term financing of our investment activities and acquisitions. At June 30, 2019, we had $76,500 on unused capacity under our line of credit, subject to covenant restrictions. In addition, in June 2018, the SEC declared effective a shelf registration statement which allows us to sell, in one or more public offerings, common stock, warrants, or any combination of such securities for proceeds in an aggregate amount of up to $300,000. The terms of any offering, including the type of securities involved, would be established at the time of sale.
Dividends
We have paid regular quarterly dividends since 2003. We declared and paid dividends of $0.16 per share for the three months ended June 30, 2019 as well as each quarter for the year ending March 31, 2019.
In July 2019, we announced that our Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, payable on September 16, 2019, to shareholders of record at the close of business on August 30, 2019.
Cash Flows
Our cash flows from operating, investing, and financing activities were as follows (in thousands):
| Three Months Ended June 30, 2019 | 2018 | |
|---|---|---|
| Net cash provided by operating activities | $724 | $6,543 |
| Net cash used in investing activities | (2,781) | (300) |
| Net cash used in financing activities | (915) | (4,442) |
Cash flows from operations were lower in the three months ended June 30, 2019 due to lower working capital, including the impact of adoption of ASU 842, as well as higher payments made for incentive compensation and federal income taxes. Cash used in investing increased as a result of the acquisition of IBP. Cash used in financing decreased during the three months ended June 30, 2019 compared to June 30, 2018 due to lower debt repayments.
Contractual Obligations and Other Commercial Commitments
We are party to many contractual obligations that involve commitments to make payments to third parties in the ordinary course of business. For a description of our contractual obligations and other commercial commitments as of March 31, 2019, see our Form 10-K for the fiscal year ended March 31, 2019, filed with the Securities and Exchange Commission on June 3, 2019. During the current quarter, there were no material changes with respect to the nature of our contractual obligations and other commercial commitments outside the ordinary course of business. At June 30, 2019, we had contractual obligations for open purchase orders of approximately $4,516 for routine purchases of supplies and inventory, which are payable in less than one year.
Off-Balance Sheet Arrangements
As of June 30, 2019, we had no off-balance sheet arrangements or obligations.
Critical Accounting Estimates
Critical accounting estimates are those that we believe are both significant and require us to make difficult, subjective, or complex judgments, often because we need to estimate the effect of inherently uncertain matters. These estimates are based on historical experience and various other factors that we believe to be appropriate under the circumstance. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended March 31, 2019 in the Critical Accounting Policies and Estimates section of “Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.”
Market risk
As filed, 513 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We have no derivative instruments and minimal exposure to commodity market risks. A portion of our operations consist of activities outside of the U.S. and we have currency risk on the transactions in other currencies and translation adjustments resulting from the conversion of our international financial results into the U.S. dollar. However, a substantial majority of our operations and investment activities are transacted in U.S. dollars and therefore our foreign currency risk is not material at this date.
Controls and procedures
As filed, 1,856 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our internal control over financial reporting as of June 30, 2019 based on the framework in “Internal Control – Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013. Based on that evaluation, our management concluded that our internal control over financial reporting was effective at June 30, 2019.
Changes in Internal Control Over Financial Reporting
On April 1, 2019, we adopted the new lease standard, as discussed in Note 1. "Description of Business and Summary of Significant Accounting Policies" and Note 4. "Leases" accompanying the Condensed Consolidated Financial Statements included within Item 1. “Financial Statements” of this report. As a result, we made additions and/or modifications to policies, procedures, systems and controls that have materially affected our internal control over financial reporting, including changes to accounting policies and procedures, operational processes and documentation practices.
Risk factors
As filed, 1,913 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are affected by risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition, or operating results are described in our Annual Report on Form 10-K for the year ended March 31, 2019, under the heading “Part I – Item 1A. Risk Factors.” Except as set forth below, there have been no material changes in our risk factors since our annual report on Form 10-K for the year ended March 31, 2019.
Changes to policy regarding the treatment of kidney disease may adversely decrease demand for our Dialysis products and negatively impact our financial statements.
During the three months ended June 30, 2019, an executive order was signed by the President of the United States that is intended to change the way that kidney care is delivered to patients and reimbursed through government-sponsored medical programs. The executive order has three key objectives: to increase the supply of kidneys available for transplants, to improve prevention and treatment of chronic kidney disease, and to encourage most dialysis patients to receive treatments through in-home care, rather than in a dialysis clinic. The extent of the impact of the executive order, as well as the timing of the impact on procedures and the market in general is currently unknown. Currently, our Dialyguard product line accounts for approximately one-third of the revenues and gross margin associated with our Instruments Division. The majority of the revenues in our Dialyguard business are associated with products that are used in dialysis clinics, while only a portion of our sales relate to in home care. If the executive order is successful at limiting the use of dialysis clinics, our financial statements, and the revenues and profits of the Instruments Division may be negatively impacted.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $26.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $10.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2019-04-01 to 2019-06-30 | $16.1m | us-gaap:GrossProfit |
| Research and development | 3 months2019-04-01 to 2019-06-30 | $1.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | $5.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2019-04-01 to 2019-06-30 | $763.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-04-01 to 2019-06-30 | $4.6m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | $1.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-04-01 to 2019-06-30 | $1.18 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-04-01 to 2019-06-30 | 4,086,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2019-04-01 to 2019-06-30 | $724.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 3 months2019-04-01 to 2019-06-30 | $624.0k | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2019-06-30 | $7.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $33.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $159.7m | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $21.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $40.6m | us-gaap:Liabilities |
| Long-term debt | At period end2019-06-30 | $17.5m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2019-06-30 | $2.3m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2019-06-30 | $119.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-19-014870. Last ingested by Listed: Nov 13, 2026, 07:45 ET. Listed shows no prices and gives no investment advice.